Skip to main content

Press & Media

Press & Media

U.S. FDA Grants Artera Breakthrough Device Designation for AI-Powered Software Transforming Prostate Cancer Care

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced to [...]

Read more

Press & Media

Multimodal AI Shows No Evidence of Bias in Prostate Cancer Study

The study evaluated the performance of a multimodal artificial intelligence model to close gaps in care and validate that AI [...]

Read more

Press & Media

Artera Bullish on Prostate Cancer Test Following NYS Approval, Impending Registry Study

NEW YORK – Startup firm Artera is continuing to make commercial progress with its artificial intelligence-based prostate canc [...]

Read more

Press & Media

AI News: Artera presented data at #ASCO25 showing that its AI platform can identify prostate cancer patients most likely to benefit (or not benefit) from added androgen receptor inhibitor therapy

CMO Tim Showalter describes the finding, which was selected as a "Best of ASCO" oral presentation. Plus, helping to determine [...]

Read more

Press & Media

Artera Launches Registry Trial to Measure Real-World Impact and Outcomes of its Prostate Test

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced th [...]

Read more

Press & Media

How AI Is Helping Cancer Patients: Saving Lives And Money

Cancer treatment is costly. The average cost of cancer care in the U.S. is around $150,000 per patient—more than four times t [...]

Read more

Press & Media

The ArteraAI Prostate Test Enhanced with New Insights for Higher Risk Patients with Localized Prostate Cancer

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has updated [...]

Read more

Press & Media

Artera Presenting Validation Data at 2025 ASCO Annual Meeting Highlighting How Multimodal AI Platform (MMAI) is Advancing Personalized Cancer Care

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announ [...]

Read more

Press & Media

TIME100 Health: Andre Esteva

Andre Esteva is pioneering a future where AI can personalize therapies to improve health. “Doctors are the first to tell you [...]

Read more

1 2 3 9